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Summary Carcinomas of the exocrine pancreas respond poorly to most chemotherapy regimens. Recently
continuous infusional 5-fluorouracil (200 mg m2day') with 3 weekly cisplatin (60 mg m ) and epirubicin
(50 mg m-2) (the ECF regimen) has proven to be an active regimen in gastric and breast cancer and
consequently worthy of further study in pancreatic cancer. Thirty-five patients were treated with the ECF
regimen as above, of whom 29 were evaluable for response and 32 were evaluable for toxicity. The mean age
was 59 years (range 37-75). Sixteen patients had locally advanced disease at presentation and 19 had
metastases. Objective tumour responses were documented in five (17.3%) patients who achieved a partial
response; in 18 (62%) patients there was no change and six (20.7%) patients progressed on therapy. Patients
with either stable disease or partial response had a significantly improved overall survival (median=253 days)
compared with patients who progressed (median = 170 days; P= 0.01). Grade 3/4 (WHO) toxicity (all cycles)
included alopecia in 18 (56%) patients, nausea/vomiting in eight (25%) stomatitis in three (9%) and diarrhoea
in seven (22%) patients, with rhinorrhoea and excessive lacrimation in one patient each. Neutropenic sepsis
occurred in 13 cycles in ten patients, and there was one toxic death due to sepsis. There were eight other
episodes of non-neutropenic sepsis requiring hospital admission. Fourteen patients (40%) experienced
complications with their Hickman lines, including thrombotic episodes (six patients) or their line falling out
(five patients). ECF can prolong survival in patients with locally advanced or metastatic pancreatic cancer who
demonstrate a response or stabilisation of their disease. However, this is associated with considerable toxicity.
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Carcinoma of the exocrine pancreas is the fifth commonest
cancer and the fourth commonest cause of cancer deaths in
the UK (Williamson, 1988). Conventional methods of
treatment including surgery, radiotherapy and chemotherapy
offer little hope of cure and the 5 year survival is reported as
less than 1% with a median survival of 2.8 months (Cancer
of the Pancreas Task Force Group, 1981).
Cancer of the pancreas responds poorly to most single-
agent chemotherapy regimens, with the best response rates
occurring with 5-fluorouracil (5-FU) (21-26%) (Carter,
1975; Moertel, 1976), ifosfamide (26%) (Bernard et al.,
1986) and epirubicin (22%) (Wils et al., 1985). Recently
response rates of 21% (Wils et al., 1993) have been reported
using cisplatin. Furthermore, the results of combination
chemotherapy have also been disappointing, with objective
response rates of only 10% using 5-FU with BCNU, (Kovach
et al., 1974), 10% with 5-FU and mitomycin C (Buroker et
al., 1979) and 14% with either FAM (5-FU, doxorubicin,
mitomycin-C) or SMF I (5-FU, streptozotocin, mitomycin C)
(Oster et al., 1986).
In patients with colorectal cancer (Lokich et al., 1989) and
breast cancer (Anderson, 1993) higher response rates have
been achieved when 5-FU is given as a continuous
intravenous infusion rather than by intermittent bolus
schedules. Moreover there is evidence that cisplatin and 5-
FU have synergistic anti-neoplastic activity (Scanlon et al.,
1986; Trave et al., 1985). Continuous infusion of low-dose 5-
FU with cisplatin and epirubicin (the ECF regimen) has been
reported to be a highly active regimen in the management of
breast cancer (Jones et al., 1994) and gastro-oesophageal
cancer (Findlay et al., 1994). Consequently we considered this
regimen worthy of evaluation in the management of patients
with inoperable carcinoma of the exocrine pancreas.
Patients and methods
All patients entered into this study had histologically or
cytologically confirmed adenocarcinoma of the pancreas.
Inoperability was determined either on the basis of clinical
evaluation and radiological imaging, or by laparotomy and
failed resection. Eligibility included at least one site of disease
that was measurable bidimensionally, the ability to manage an
indwelling (i.v.) catheter, and adequate haematological
function (WBC 4x 109 1-l, platelets l00x 109 1-'). Pa-
tients who had received chemotherapy previously were not
eligible, but patients who had received radiotherapy to
individual sites of disease were eligible, although the irradiated
site was considered non-evaluable for response. Patient
performance status was assessed using the World Health
Organization (WHO) criteria (Miller et al., 1981) and those
patients with performance status < 2 were considered eligible
for this study. All patients gave informed, verbal consent.
Intravenous access
All chemotherapy was given via a double-lumen indwelling
Hickman catheter (Davol, Cranston, USA) placed in the
subclavian vein via a subcutaneous tunnel (Stacey et al.,
1991). Prophylactic low-dose warfarin (1 mg day-') was
administered to reduce the incidence of venous thrombosis
associated with indwelling central venous catheters (Bern et
al., 1990), and continued for the duration of the treatment.
On the day of insertion, prophylactic flucloxacillin 500 mg
q.d.s. orally was started and continued for a total of 5 days.
Subsequent infections of the exit site were treated with a
course of appropriate antibiotic based on the microbiology.
Venous thrombosis associated with the Hickman line was
managed by removal of the line and full anticoagulation,
which was continued throughout treatment.
Chemotherapy
5-FU was given intravenously as a continuous infusion at a
dose of 20 mg m-2 day-' via the central venous line.
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Portable battery-powered infusion pumps [Infumed, Medox
(Medifusion), USA] were used to administer the chemother-
apy in the ambulatory setting. If patients developed plantar-
palmar erythema, pyridoxine 50 mg t.d.s. orally was
administered. If this toxicity did not improve, the 5-FU
was reduced to 150 mg m-2 day-'. If patients developed
mucositis or diarrhoea the 5-FU was discontinued until these
symptoms had resolved and was restarted with a 25% dose
reduction. The 5-FU was administered for a total of 15
weeks, and stopped the day after the last of the 3 weekly
cisplatin and epirubicin injections.
The cisplatin was administered at a dose of 60 mg m-2 on
day 1 of the treatment and then every 21 days for a total of 6
cycles. This was given with standard pre- and postchemother-
apy hydration protocols with potassium and magnesium
supplements. Dose adjustment criteria for cisplatin were
based on glomerular filtration rate (GFR), which was
estimated using 5"Cr-[EDTA] clearance or 24 h urinary
creatinine clearance. If the GFR was greater than or equal
to 60 ml min-1, full-dose cisplatin was given. If the GFR was
40-60 ml min-m, a 25% dose reduction was performed for
the patients treated at the start of the study, although this
was subsequently modified so that the mg dose of cisplatin
equalled the GFR value in ml min-'. This modification also
applied to patients with a pretreatment GFR of 40-
60 ml min-' for the first dose of cisplatin. If the GFR was
<40 ml min-', either pretreatment or during ECF che-
motherapy, carboplatin was substituted for cisplatin, and
the dose calculated using the formula devised by Calvert et
al. (1989).
Epirubicin (50 mg m-2) was given as an intravenous bolus
every 3 weeks immediately before the cisplatin. All patients
had a baseline electrocardiogram (ECG), and if this was
abnormal or there was a past history of cardiac disease, a
pretreatment echocardiogram was also performed. With
myelosuppression (white cell count <3.0 x l09 1-', platelets
< 100 x 109 -1') at the time of the next cycle, treatment was
delayed for 1 week or until the myelosuppression had
resolved. In the presence of a second episode of treatment
delay due to myelosuppression or an episode of neutropenic
sepsis, a 25% dose reduction of the epirubicin would be given
on subsequent treatments. If the patient's bilirubin was
significantly elevated, usually as a result of resolving biliary
obstruction, then the epirubicin dose was reduced appro-
priately, although this would be subsequently increased if the
liver function tests improved sufficiently.
Evaluation of response and toxicity
Response evaluation was based on the WHO criteria (Miller
et al., 1981). Complete response was defined as the complete
disappearance of all known disease for at least 4 weeks.
Partial response was defined as a 50% or greater reduction in
the sum of the products of the longest tumour diameter and
its longest perpendicular for at least 4 weeks, in the absence
of the appearance of a new lesion or progression in any
existing lesion. No change was defined as < 50% reduction in
the total tumour size or an increase of <25% in one or more
lesions. Progressive disease was defined as an increase of
>25% in one or more lesions, or the appearance of any new
lesion. Following pretreatment evaluation, a computerised
tomography (CT) scan was repeated after cycles 3 and 6.
Patients were not routinely restaged during follow-up and as
most did not have clinically assessable disease, the exact time
of disease relapse or progression was not documented for
most patients. Overall survival was taken to be the more
relevant end point and was measured from the day of starting
chemotherapy until the date of death. Survival was measured
in days and compared using the chi-squared test after log-
rank analysis using the Clinstat program.
Chemotherapy toxicity was graded using the WHO criteria
(Miller et al., 1981). Plantar-palmer erythema was graded
using the WHO skin criteria. For each patient the toxicity
was recorded as the worst toxicity for all cycles. Central
venous line complications, including thromboembolic events,
were documented, as were treatment-related deaths.
Results
Patient characteristics
Thirty-five eligible patients from St George's Hospital,
London, were recruited between February 1991 and August
1994. The patient characteristics and baseline performance
status are summarised in Table I. Four patients had received
previous therapy for their pancreatic tumours: three radio-
therapy and one patient tamoxifen. No patient had
previously received cytotoxic chemotherapy.
Tumour response
Twenty-nine patients were evaluable for response. Three
patients were evaluble for toxicity but not for response, as
they did not survive long enough for a response assessment to
be done. Three patients who died shortly after their first cycle
of chemotheraphy from non-treatment-related causes were
not evaluable for response to toxicity.
A partial response was documented in five (17.3%)
patients. There were no complete responses. Of these five
patients, two had locally advanced disease, one had
peritoneal disease and coeliac lymph nodes, one had porta
hepatis lymphadenopathy and one patient had documented
partial response of both skin deposits and cerebral
Table I Patient characteristics (n = 35)
Age
Mean
Range
Sex
Male
Female
Histology
Adenocarcinoma
Differentiation
Well
Moderate
Poor
Unknown
Disease at presentation
Locally advanced
Metastatic
Performance status (ECOG) (baseline)
0
1
2
Not recorded
Site of primary tumour
Head
Body
Tail
Body/tail
Peri-ampullary
Uncinate process
Neck
Site of metastatic disease at presentation
Liver
Lymphadenopathy
Omentum
Peritoneum
Brain
Pleural effusion
Lung parenclyma
Large bowel
Adrenal gland
Skin
59 years
37-75 years
21
14
35
5
11
2
17
16
19
10
20
1
4
23
2
2
3
2
2
1
10
10
2
2
l
1
1
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metastases. Of these five patients, two had documented
partial response at initial restaging (after three cycles of
chemotherapy) that was maintained at restaging on comple-
tion of chemotherapy (five and six cycles). All three
remaining patients also achieved partial response at initial
restaging. However, one patient died of neutropenic sepsis
shortly after this response was documented. The two other
patients both discontinued chemotherapy after four cycles
because of toxicity, and therefore were not routinely restaged
at that time. One of these two patients clinically developed
progressive disease 5 months after stopping chemotherapy,
which was confirmed on CT. The other patient died 10
months after completing chemotherapy. In 18 patients
(62.1 %) there was no change, and progressive disease
occurred in six (20.7%) of the evaluable patients. Twelve
(66%) of the 18 patients with stable disease completed all six
cycles of chemotherapy.
Treatment toxicity
Thirty-two patients who received a total of 150 cycles of
chemotherapy were evaluable for toxicity. Specific treatment
toxicities are detailed in Table II. There were 13 episodes of
documented neutropenic sepsis, which occurred in ten
patients and a further eight clinically significant infective
episodes, which occurred in the absence of neutropenia in
seven patients.
Chemotheraphy was discontinued before the planned six
courses of chemotherapy in 21 (60%) patients. This was due
to documented progressive disease at initial restaging in four
patients, death in eight patients, unacceptable toxicity in
seven patients and recurrent Hickman line complications in
one patient.
There were eight patients who died while still undergoing
chemotherapy, of which only one death was definitely
attributed to treatment toxicity, namely a patient who
developed renal failure, neutropenic sepsis and died on day
10 of cycle 3 of the ECF. Two patients died suddenly at
home, one on day 6 of cycle 3 and one on day 16 of cycle 2.
In both cases no autopsy was performed and the cause of
death was unknown and treatment-related causes of death
cannot be excluded. One patient with documented stable
disease died of complications arising from his underlying
tumour (biliary stent infection, gastrointestinal bleeding) after
his fourth cycle of chemotherapy, and one patient died of a
pulmonary emoblism on admission for her third course of
treatment.
Three patients died after only one course of treatment; one
patient sustained a cerebrovascular accident as a consequence
of a hypercoaguable state, another died from a profuse
gastrointestinal haemorrhage and the third patient died of
pneumonia (with no evidence of neutropenia) 3 days after
starting treatment.
Fourteen patients (40%) experienced complications from
their Hickman lines including thrombosis in the vein in which
the Hickman line was placed (six patients), Hickman lines
falling out (five), pain necessitating line removal (two),
infection (one), wrong positioning at insertion (one) and
splitting of the line on insertion (one).
Table II Treatment toxicities: worse toxicity per patient (all cycles)
(n = 32)
Grade 1/2 (WHO) Grade 3/4 (WHO)
Toxicity Number % Number %
Emesis 16 (50) 8 (25)
Alopecia 13 (41) 18 (56)
Diarrhoea 16 (50) 7 (22)
Oral mucositis 22 (69) 3 (9)
Lacrimation 3 (9) 1 (3)
Rhinorrhoea 1 (3) 1 (3)
Dose delays and dose reductions
Chemotherapy was delayed on 11 occassions in eight
patients, and this was due to either inadequate WBC
recovery (five cycles), ongoing sepsis (three), oral toxicity
(one) or awaiting re-insertion of a Hickman line (two). The
dose of epirubicin was reduced by >25% in 13 (37%)
patients because of either previous neutropenic sepsis (31
cycles), an elevated bilirubin due to biliary obstruction (eight
cycles) or because of repeated treatment delays (two cycles).
Despite reducing the epirubicin in patients with abnormal
liver function tests due to biliary obstruction, neutropenic
sepsis still occurred after occurred after one of the eight
cycles of modified chemotherapy.
The dose of cisplatin was modified in 20 of 35 patients,
with four patients receiving a total of 17 cycles of
chemotherapy containing carboplatin instead of cisplatin.
Neutropenic sepsis occurred with 6 of the 17 cycles and
platelet support was also required in the nadir of 6 of these
17 cycles of chemotherapy. Platinum agents were omitted
during the treatment for three patients because of renal
impairment (two patients) and hearing loss (one).
Nineteen patients had either a reduction (13 patients) or
an interruption of the infusional 5-FU (18). Dose reductions
were due mainly to gastrointestinal toxicity with or without
reported neutropenic infections.
Survival
Survival data are summarised in Tables III, IV and V. The
exact date of death was unknown in two patients who were
lost to follow-up after completing chemotherapy; it is known
that both have died. There was no significant difference in the
survival of patients with a partial response compared with
those with either stable disease or progressive disease,
although the number of responses is small (n = 5). However,
when patients with either stable disease (median survival 253
days) or partial response (median survival 253 days) are
considered together, they have a significantly improved
Table III Survival data comparisons of locally advanced with
metastatic disease (irrespective of response)
Disease
status n Median (days) Mean (days) Range (days)
Locally 15 237 222.8 4 -459-
advanced P= 0.22
Metastatic 18 181 172.3 11 -395-
In two patients date of death is unknown
Table IV Survival data according to patient response
Median Mean Range
Response n (days) (days) (days)
Partial response 5 253 227.6 57-386
Stable disease 17 253 258.4 98 -459
Progressive disease 5 170 147.8 54-237
Six patients were non-evaluable.
Table V Survival data according to baseline patient performance
status
Performance status Number Median survival (days)
All patients 10* 237*
0* 18* 196.5*
1*
Stable disease
0** 7** 253**
I ** 14** 234.5**
*P=0.51. **P =0.44.
ECF in pancreatic cancer
TRJ Evans et a! %
1263
overall survival compared with patients who progressed
during treatment (median survival 170 days; P=0.01). For
the patients with stable disease or a partial response, there
was on significant difference in overall survival for patients
with locally advanced (n = 11) compared with metastatic
disease (n = 11, P= 0.28). Furthermore, there was no
significant difference in survival between patients with
baseline performance status 0 (n = 10) and performance
status 1 (n= 18) (P=0.51). Moreover, when patients with
partial response and stable disease were analysed, there was
no significant survival difference between these two groups on
the basis of baseline performance status (P=0.44).
Discussion
Carcinoma of the pancreas is inoperable in most cases, and
as the responses to radiotherapy and chemotherapy are so
poor it is almost inevitably fatal. Nevertheless, previous
studies have shown that palliative chemotherapy does
improve overall survival compared with no treatment
without impairing quality of life (Leonard et al., 1992;
Mallinson et al., 1980; Palmer et al., 1994). Consequently,
attempts to devise new chemotherapy regimens with the aim
of improving response rates and overall survival are justified.
The primary objective of the study was to evaluate the
ECF regimen in pancreatic cancer, to assess the response
rate, toxicity and patient survival, particularly in view of the
activity of this regimen in gastro-oesophageal and breast
cancers. The partial response rate in this *study (17.3%)
remains low compared with the response rates observed for
gastro-oesophageal (71%) (Findlay et al., 1994) and breast
cancer (84%) (Jones et al., 1994). Furthermore, the response
rate to ECF in pancreatic cancer is only marginally better
than the responses reported with FAM or SMF I (14%)
(Oster et al., 1986), 5-FU plus BCNU (10%) (Kovach et al.,
1974) or 5-FU plus mitomycin C (10%) (Buroker et al.,
1979), or continuous infusional 5-FU with cisplatin (16%)
(Rothman et al, 1991), and is less than that observed for a 5
day infusion of 5-FU with a single cisplatin dose (26%)
(Rougier et al., 1993). There was no significant difference in
survival between patients with locally advanced disease and
those with metastatic disease. However, patients with either a
documented partial response or stable disease with ECF have
a significantly improved survival from starting chemotherapy
compared with patients whose disease progressed on ECF
(P=0.01). Moreover, the overall survival for patients with
stable disease or a partial response is greater than that which
is said to occur in untreated patients. It may be that in
inoperable pancreatic cancer, which carries such a poor
prognosis, stable disease may represent a significant palliative
response, although randomised studies would be necessary to
confirm this.
Nevertheless, there was considerable toxicity with this
regimen. There was one definite treatment-related death
which compares with the 4.3% treatment-related death rate
with ECF in gastro-oesophageal cancers (Findlay et al.,
1994). The cause of death in two other patients who died at
home while undergoing treatment was unknown. The other
five deaths that occurred during treatment were not thought
to be treatment-related. A further seven patients discontinued
chemotherapy because of unacceptable toxicity, and one
because of persistent and recurrent Hickman line complica-
tions. Despite anticoagulation with 1 mg day-' warfarin
there was a high (17%) incidence of venous thrombosis
associated with the Hickman catheter in comparison with the
other studies (breast 9%, gastrointestinal 4%). This likely to
be because of the high incidence of hypercoaguable state that
occurs in pancreatic carcinoma (Sack et al., 1977; Sproule et
al., 1938) and we have since increased the daily warfarin to
2 mg in patients with pancreatic cancer on the ECF regimen
to try to reduce the incidence of this complication. Moreover
although fourteen (40%) patients received the six courses of
ECF chemotherapy only two patients received all six cycles of
ECF without a dose reduction or delay.
Thus, the ECF regimen can prolong survival in patients
with locally advanced or metastatic carcinoma of the
pancreas. In this group of patients the toxicity is consider-
ably higher when compared with patients receiving the same
chemotherapy for breast or gastrointestinal cancers and
highlights the need for very careful patient selection in
terms of who is likely to benefit. The search for more active
and less toxic drugs continues, and perhaps emphasises the
importance of randomised studies with the inclusion of a best
supportive care arm so that an objective assessment of
quality of life and survival can be made.
Acknowledgements
We are grateful to all the staff at St George's Hospital who helped
to look after the patients in this study, and to Sheryl Pond for
typing this manuscript.
References
ANDERSON NR. (1993). 5-Fluorouracil: a re-appraisal of optional
delivery in advanced breast cancer. J. Infusional Chemother., 3,
111-118.
BERN MM, LOKICH JJ, WALLACH SR, BOTHE A, BEROTTI PN,
ARTIN CF, GRECO FA, HUBERMAN M AND MOORE C. (1990).
Very low doses of warfarin can prevent thrombosis in central
venous catheters. Ann. Intern. Med., 112, 423 -428.
BERNARD S, NOBLE S, WILCOSKY T, ATILGREN J, AND SMITH FP.
(1986). A phase II study of ifosfamide (IFOS) plus N-acetyl
cysteine (NAC) in metastic measurable pancreatic adenocarcino-
ma (abstract). Proc. Am. Soc. Clin. Oncol., 5, 328.
BUROKER T, KIM PN, GROPPE C, MCCRACKEN J, O'BRYAN R,
PANETTIERE F, COSTANZI J, BOTTOMLEY R, KING GW,
BONNET J, THIGPEN T, WHITECAR J, HANS C, VAITKEVICUS
VK, HOOGSTRATEN B AND HEILBURN L. (1979). 5-FU infusion
with mitomycin C vs 5-Fu infusion with methyl CCNU in the
treatment of advanced upper gastrointestinal cancer. Cancer, 44,
1215- 1221.
CALVERT AH, NEWELL DR, GUMBRELL LA, O'REILLY S,
BURNELL M, BOXALL FE, SIDDIK ZH, JUDSON IR, GORE M,
AND WILTSHAW E. (1989). Carboplatin dosage: prospective
evaluation of a simple formula based on renal function. J. Clin.
Oncol., 7, 1748-1756.
CANCER OF THE PANCREAS TASK FORCE GROUP. (1981). Staging
of cancer of the pancreas. Cancer, 47, 1631 - 1637.
CARTER SK. (1975). The intergration of chemotherapy into a
combined modality approach for cancer treatment: VI. Pancreatic
adenocarcinoma. Cancer Treat. Rev., 3, 193-214.
FINDLAY M, CUNNINGHAM D, NORMAN A, MANSI J, NICOLSON
M, HICKISH T, NICOLSON V, NASH A, SACKS N, FORD H,
CARTER R AND HILL A. (1994). A phase II study in advanced
gastro-esophageal cancer using epirubicin and cisplatin in
combination with continuous infusion 5-fluorouracil (ECF).
Ann. Oncol., 5, 609-616.
JONES AL, SMITH IE, O'BRIEN MER, TALBOT D, WALSH G,
RAMAGE F, ROBERTSHAW H AND ASHLEY S. (1994). Phase II
study of continuous infusion 5-fluorouracil with epirubicin and
cisplatin in patients with metastatic and locally advanced breast
cancer: an active regimen. J. Clin. Oncol., 12, 1259-1265.
KOVACH JS, MOERTEL CG, SCHUTT AJ, HAHN RG AND REITE-
MEIER RJ. (1974). A controlled study of combined 1, 3-bis-(2-
chlorethyl)-l-nitrosurea and 5-fluorouracil therapy for advanced
gastric and pancreatic cancer. Cancer, 33, 563 - 567.
LEONARD RCF, CULL A, STEWART ME, KNOWLES G, CARTER DC
AND PALMER KR. (1992). FAM chemotherapy prolongs survival
in pancreatic cancer; Quality of life is unimpaired. (abstract).
Annal. Oncol., 3, (suppl. 5), 24, 92.
ECF in pancreatic cancer
1264 TRJ Evans et al
1264
LOKICH JJ, AHLGREN JD, GULLO SJ, PHILIPS JA AND FRYER JG.
(1989). A prospective randomised comparison of continuous
infusion fluorouracil with a conventional bolus schedule in
metastatic colorectal carcinoma. A Mid-Atlantic Oncology
Program Study. J. Clin. Oncol., 7, 425 -432.
MALLINSON GN, RAKE MO, COCKING JB, FOX CA, CWYNARSKI
MT, DIFFEY BL, JACKSON GA, HANLEY J AND WASS VJ. (1980).
Chemotherapy in pancreatic cancer: results of a controlled,
prospective, randomised, multicentre trial. Br. J. Med. J., 281,
1589- 1591.
MILLER AB, HOOGSTRATEN B, STAQUET M AND WINKLER A.
(1981). Reporting results of cancer treatment. Cancer, 47, 207-
214.
MOERTEL CG. (1976). Chemotherapy for gastrointestinal cancer.
Clin. Gastroenterol., 5, 777-793.
OSTER MW, GRAY R, PANASCI L AND PERRY MC. (1986).
Chemotherapy for advanced pancreatic cancer: A comparison
of 5-fluorouracil, adriamycin and mitomycin - c (FAM) with 5-
fluorouracil, streptozotocin and mitomycin-C (FSM). Cancer, 57,
29-33.
PALMER KR, KERR M, KNOWLES G, CULL A, CARTER DC, AND
LEONARD RCF. (1994). Chemotherapy prolongs survival in
inoperable pancreatic carcinoma. Br. J. Surg., 81, 882-885.
ROTHMAN H, CANTRELL JE JR., LOKICH J, DIFINO S, HARVEY J,
AHLGREN J AND FRYER J. (1991). Continuous infusion 5-
fluorouracil plus weekly cisplatin for pancreatic carcinoma. A
mid-Atlantic Oncology Program Study. Cancer, 68, 264-268.
ROUGIER P, ZARBA JJ, DUCREUX M, BASILE M, PIGNON JP,
MAHJOUBI M, BENAHMED M, DROZ JP, CVITKOVIC E AND
ARMAND JP. (1993). Phase II study of cisplatin and 120-hour
continuous infusion of 5-fluorouracil in patients with advanced
pancreatic adenocarcinoma. Annal. Oncol., 4, 333-336.
SACK GH JR, LEVIN J AND BELL W. (1977). Trousseau's syndrome
and other manifestations of chronic disseminated coagulopathy
in patients with neoplasms. Clinical, pathologic and therapeutic
features. Medicine, 56, 1 -37.
SCANLON KJ, NEWMAN EM, LU Y AND PRIEST DG. (1986).
Biochemical basis for cisplatin and 5-fluorouracil synergism in
human ovarian carcinoma cells. Proc. Natl Acad. Sci. U.S.A., 83,
8923 - 8925.
SPROULE EE. (1938). Carcinoma and vericus thrombosis. The
frequency of association of carcinoma in the body or tail of the
pancreas with multiple venous thrombosis. Am. J. Cancer, 34,
566- 585.
STACEY RGW, FILSHIE J AND SKEWES D. (1991). Percutaneous
insertion of Hickman-type catheters. Br. J. Hosp. Med., 46, 396-
398.
TRAVE F, RUSTUM YM AND GORANSON J. (1985). Synergistic anti-
tumour activity of cisplatin (DDP) and 5-fluorouracil (FUra) in
mice bearing leukemia C1210 cells. Proc. Am. Assoc. Cancer Res..
25, 1270.
WILLIAMSON RCN. (1988). Pancreatic Cancer: the greatest
oncological challenge. Br. Med. J., 296, 445 -446.
WILS J, BLEIBERG H, BLIJHAM G, DALESIO 0, DUEZ N, LACAVE A
AND SPLINTER T. (1985). Phase II study of epirubicin in
advanced adenocarcinoma of the pancreas. Eur. J. Cancer Clin.
Oncol., 21, 191-194.
WILS J, KOK T, WAGENER OJ, SELLESLAGS J AND DUEZ N. (1993).
Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J.
Cancer, 29, 203-204.
